A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc

Affiliations

• ¹ New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Tulane University School of Medicine, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA. Electronic address: [email protected].
• ² Vanderbilt University Medical Center, Nashville, TN, USA.
• ³ Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary.
• ⁴ University of Pittsburgh, Pittsburgh, PA, USA.
• ⁵ Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Steffens Scleroderma Foundation, Albany, NY, USA.
• ⁶ Department of Rheumatology at Hospital for Special Surgery, New York, NY, USA.
• ⁷ Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
• ⁸ Perelman School of Medicine, Philadelphia, PA, USA.
• ⁹ Steffens Scleroderma Foundation, Albany, NY, USA; Division of Rheumatology, Albany Medical Center, Albany, NY, USA.
• ¹⁰ Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, NM, USA.
• ¹¹ University of California, David Geffen School of Medicine, UCLA Scleroderma Program and UCLA CTD-ILD Program, Division of Rheumatology, Department of Medicine, Los Angeles, CA, USA.
• ¹² Ochsner Medical Center, New Orleans, LA, USA.
• ¹³ Norton Thoracic Institute, St. Joseph's Hospital and Medical Centre, Phoenix, AZ, USA.
• ¹⁴ Function Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden; Department of Medicin, Solna, Karolinska Institutet, Stockholm, Sweden.
• ¹⁵ Division of Rheumatology, Medical University of South Caroline, SC, USA.
• ¹⁶ Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
• ¹⁷ Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
• ¹⁸ Department of Internal Medicine, Ghent University, and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
• ¹⁹ Rutgers- RWJ Scleroderma Program, New Brunswick, NJ, USA.
• ²⁰ Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
• ²¹ Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
• ²² Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genova, Italy.
• ²³ Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP) São Paulo, SP, Brazil.
• ²⁴ Department of Rheumatology, George Washington University, School of Medicine and Health Sciences, Washington, DC, USA.
• ²⁵ Department of the rheumatic diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
• ²⁶ Patient Research Partner, Scleroderma & Raynaud Society UK (SRUK), London, UK; Royal Free Hospital, London, UK.
• ²⁷ Patient Research Partner, Scleroderma Foundation, Chicago, IL, USA.
• ²⁸ Scleroderma Foundation, Danvers, MA, USA.
• ²⁹ Federation of European Scleroderma Associations, Copenhagen, Denmark; Federation of European Scleroderma Associations, Budapest, Hungary; Federation of European Scleroderma Associations, London, UK.
• ³⁰ Scleroderma Canada, Canada.
• ³¹ Patient Research Partner, Scleroderma & Raynaud Society UK (SRUK), London, UK; Federation of European Scleroderma Associations, Copenhagen, Denmark; Federation of European Scleroderma Associations, Budapest, Hungary; Federation of European Scleroderma Associations, London, UK.
• ³² Columbia University/New York-Presbyterian Scleroderma Program, Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
• ³³ Tulane University School of Medicine, New Orleans, USA; Oregon Health and Science University, Portland, OR, USA.
• ³⁴ Yale School of Medicine, Department of Internal Medicine, Section of Rheumatology, Allergy & Immunology, USA.
• ³⁵ Division of heumatology and Department of Medicine, Jewish General Hospital and McGill University, Montreal, QC, Canada.
• ³⁶ New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA.
• ³⁷ Tulane University School of Medicine, New Orleans, USA.
• ³⁸ Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
• ³⁹ Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA.
• ⁴⁰ University of Melbourne, Melbourne at St. Vincent's Hospital Melbourne, Victoria, Australia.
• ⁴¹ Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Lübeck, University Clinic of Schleswig-Holstein, Dept Rheumatology and Clinical Immunology, Lübeck, Germany.
• ⁴² University of Exeter, College of Medicine and Health, Exeter, UK.
• ⁴³ University of Utah, Division of Pulmonary Medicine, Pulmonary Fibrosis Center, Salt Lake City, UT, USA.
• ⁴⁴ Department of Rheumatology and Clinical Immunology Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.
• ⁴⁵ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
• ⁴⁶ Dept. of Rheumatology, Basel University Hospital, Basel, Switzerland.
• ⁴⁷ Division of Rheumatology, Department of Medicine, Georgetown University, Washington, DC, USA.